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BRFS was 77% without MF vs 17% with MF (p 0.001) 
BRFS was: PSA 0.2-1: 83%; 1.1-2: 66%; 2.1-10: 39%; >10.1: 
37%. p: 0.02  
 
Conclusion: cPET/TAC detect initial local and regional 
relapses that can be treated with local radiotherapy with or 
without hormonal therapy with good results. 
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Purpose or Objective: To prospectively evaluate the impact 
of Choline/ PSMA PET-CT imaging on management of patients 
with prostate cancer (PC). 
 
Material and Methods: Fifty patients with high risk or 
recurrent PC received a 11Choline and/or a 68Ga-PSMA-PET-
CT before radiation treatment planning within a prospective 
register study. Main subgroups were identified and only 
patients with a conventional staging before PET-CT were 
evaluated to compare treatment management decisions 
before and after PET-CT with regard to treatment intent, 
target volume (TV) definition, radiation dose and duration of 
androgen deprivation therapy (ADT). 
 
Results: The three main subgroups fulfilling the mentioned 
conditions above were high risk (HR, n=17), recurrence after 
prostatectomy (R, n=12) and R plus salvage radiotherapy 
(RSR, n=7). In HRPC, TNM-changes (n=12/17) led to treatment 
changes (n=14) including TV-changes (n=12). In R, TNM-
changes (n=8/12) resulted in treatment changes (n=8) 
including TV-changes (n=7). In the group after RSR, TNM-
changes (n=6/7) resulted in treatment changes (n=6).  
Management was changed in 82% (HRPC), 66%(R) and 
85%(RSR). Of these groups (n=36) only two patients were 
initially stratified as M1. PET-CT led to downstaging (M0) or 
diagnosed only oligometastatic disease enabling curative 
treatment in both patients. However, in 12 patients initially 
planned for curative treatment detection of N1-disease 
(n=3/9) or newly diagnosed M1-disease (n=9/11) shifted 
treatment allocation to palliative therapy.  
Taken together, curative treatment could be offered to 
initially diagnosed M1-patients (n=2). Since patients with RSR 
were usually in the palliative situation, PET-CT enabled in 
further 28% (2/7) of patients disease localization and curative 
treatment. However, of initially curatively planned patients 
(27/29) with R or HRPC, PET-CT facilitated to avoid 
overtreatment in ~30% (8/27) of patients due to early 
visualization of incurable disease. Main limitation is the 
absence of histological verification. 
 
Conclusion: PET-CT had a pronounced impact on decision 
making and management in this group of patients with high-
risk or recurrent prostate cancer. Therefore we suggest that 
PET-CT should be considered in the work-up in specific 
clinical situations. 
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Purpose or Objective: To evaluate the possible impact of 
positive margins (PM) after surgery for prostate cancer on: I) 
biochemical parameters of recurrence (immediate failure 
rate and the time to development of biochemical recurrence) 
and II) the incidence of macroscopic disease at magnetic 
resonance image (MRI) realized before salvage radiation 
therapy (SRT). 
 
Material and Methods: Data from 101 prostate cancer 
patients treated between 2012-13 was analyzed. Fifty (49.5 
%) had MRI before SRT. PSA failure was defined has a value 
greater than 0.2 ng/ml after 6 weeks after prostatectomy. 
Cases with PSA >0.2 at the first measure 6 weeks after the 
surgery were categorized (no vs yes) and considered 
separately for the analysis of immediate failure. Categorical 
analysis were done using chi-square test. The time to the 
development of biochemical recurrence was presented in 
Kaplan Meier and log-Rank test was used to compare PM vs 
negative margins (MN) group. Mann-Whitney-Wilcoxon test 
was used to compare the PSA means between groups (PM vs 
NM / macroscopic recurrence present vs absent). The 
statistical analysis was done using SPSS V.20. 
 
Results: The basic characteristics of this population were: 
age 66.8 years (median), initial PSA 8.0 ng/ml (median), 
52.6% pT2 and 34.7% pT3. The proportions of each 
pathological risk group were 7%, 42% and 51% (low-risk, 
intermediate risk, high-risk) and 43,6% had PM (n=44). Those 
with PM had an increased chance of immediate PSA failure 
(p=0.004) and an earlier development of biochemical 
recurrence (23.4 months vs 49 months, p = 0.001). The mean 
PSA of the recurrence was 1.4 (+/- 1.7) ng/ml vs 2.6 ng/ml 
(+/- 6.1) (p = 0.839), for NM and PM respectively. Patients 
with macroscopic recurrence had a greater pre-SRT PSA: 3.5 
(+/- 1.7) vs 0.8 (+/- 0.7) ng/ml. The incidence of biochemical 
recurrence with prostatic nodule in the MRI was not 
influenced by margin status (p=0.108) and marginally not 
influenced by pathological status (low or intermediate risk vs 
high risk) (p=0.062). 
 
Conclusion: PM patients have had an earlier development of 
biochemical recurrence but our series did not find a 
significant impact of margin status on the incidence of nodule 
on prostatic bed. A possible delay in the detection of the 
recurrence in margin negative patients should be evaluated 
in next studies. 
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Purpose or Objective: Recent evidences has fostered the 
emergence of Stereotactic Body Radiation Therapy (SBRT) as 
a promising treatment modality for the management of 
localized prostate cancer. In fact, given the low alpha/beta 
ratio of prostate cancer, the delivery of very high radiation 
doses in few fractions, may even improve the therapeutic 
ratio in the treatment of this disease. This phase II study was 
aimed to evaluate the efficacy and toxicity of SBRT in a 
series of patients with low or intermediate risk prostate 
cancer. 
 
Material and Methods: Biopsy confirmed prostate cancer 
patients were enrolled in this phase II trial, provided that 
they had the following characteristics: iPSA < 20 ng/ml, 
Gleason Score < 7, IPSS < 7. The treatment schedule was 35 
Gy in 5 fractions, delivered every other day with VMAT 
technology in FFF modality. Toxicity was recorded according 
